Last reviewed · How we verify
Ketorolac 0.5% eyedrops
Ketorolac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and thereby decrease inflammation and pain in the eye.
Ketorolac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and thereby decrease inflammation and pain in the eye. Used for Postoperative ocular pain and inflammation following cataract surgery, Seasonal allergic conjunctivitis, Ocular pain associated with corneal abrasion or refractive surgery.
At a glance
| Generic name | Ketorolac 0.5% eyedrops |
|---|---|
| Sponsor | Università degli Studi di Brescia |
| Drug class | Nonsteroidal anti-inflammatory drug (NSAID) |
| Target | Cyclooxygenase (COX-1 and COX-2) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
As a topical NSAID eyedrop, ketorolac blocks COX-1 and COX-2 enzymes in ocular tissues, reducing the production of inflammatory prostaglandins. This mechanism alleviates ocular pain, inflammation, and photophobia associated with various eye conditions. The 0.5% formulation delivers the drug directly to the anterior segment of the eye for local anti-inflammatory and analgesic effects.
Approved indications
- Postoperative ocular pain and inflammation following cataract surgery
- Seasonal allergic conjunctivitis
- Ocular pain associated with corneal abrasion or refractive surgery
Common side effects
- Ocular irritation or stinging
- Conjunctival hyperemia
- Headache
- Corneal epithelial defects (rare)
Key clinical trials
- Evaluating a Dropless Postoperative Regimen After Cataract Surgery in a Vulnerable, County-hospital Population (PHASE4)
- Assessment of the Effects and Tolerability of RD03/2016 for the Treatment of Bacterial Conjunctivitis in Adults (PHASE2)
- Ketorolac Levels in Vitreous and Aqueous Samples From Patients Undergoing Combined Cataract and Pars Plana Vitrectomy Surgeries With and Without Intracameral Phenylephrine 1.0% / Ketorolac 0.3% (EARLY_PHASE1)
- Efficacy of NSAID vs. Steroid-NSAID Combo Post-Selective Laser Trabeculoplasty: Phase 4, Single-Center RCT (PHASE4)
- Steroids After Laser Trabeculoplasty for Glaucoma (PHASE4)
- Nepafenac Versus Ketorolac Eye Drops in Prevention of Intraoperative Miosis During Cataract Surgery (PHASE2)
- Treatment of Post-surgical Cystoid Macular Edema With Topical Steroids Trial (TEMPEST-1) (PHASE2, PHASE3)
- Tolerability and Toxicity of Topically Applied Nepafenac 0.3% vs Ketorolac 0.5% (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ketorolac 0.5% eyedrops CI brief — competitive landscape report
- Ketorolac 0.5% eyedrops updates RSS · CI watch RSS
- Università degli Studi di Brescia portfolio CI